The effects of lipoprotein(a) and homocysteine on prognosis and risk factors in acute ischemic stroke

References

• Bogusslavsky J, Van Mele G, Regli F: The Lausanne Stroke Registry: analysis of 1000 consecutive patients with first stroke. Stroke 1988 Sep;19(9):1083–92.
   PubMedGoogle Scholar
• Hajjar KA, Gavish D. Lipoprotein (a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989 May 25;339(6222):303–5.
   PubMed Web of Science ®Google Scholar
• Kumral E. Inme Dagilimi: Dunyada Turkiye'de. Santral Sinir Sisteminin Damarsal Hastaliklari. Ankara, Turkey: Kitabevi Ltd Sti, 2011:17–20.
   Google Scholar
• Biller J, Betsy B. Ischemic cerebrovascular diseases. In: Bradley WG, ed. Neurology in clinical practice. 5th ed. Butterworth Heinemann: Elsevier; 2008;55:1165–223.
   Google Scholar
• Foody JAM, Milberg JA, Robinson K, Homocysteine and lipoprotein(a) interact to increase CAD risk in young men and women. Arterioscler Thromb Vasc Biol 2000;20(2):493–9.
   PubMedGoogle Scholar
• Sogutçu T, Kaplan A. Akut koroner sendromlu hastalarda plazma homosistein düzeylerinin akut dönemde seyri. (Tıpta uzmanlık tezi) Dicle U. Tip F. 2002;7–14.
   Google Scholar
• Poddar R, Sivasubramanian N, Dibello PMD, Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells: implications for vascular disease. Circulation 2001 Jun 5;103(22):2717–23.
   PubMed Web of Science ®Google Scholar
• Pezzini A. Homocysteine and cerebral ischemia: pathogenic and therapeutical implications. Curr Med Chem 2007;14(3): 249–63.
   PubMedGoogle Scholar
• Marcovina SM, Kennedy H, Bittolo Bon G, Fish intake, independent of apo(a) size, accounts for lower plasma lipoprotein(a) levels in Bantu fishermen of Tanzania – the Lugalawa Study. Arterioscler Thromb Vasc Biol 1999 May;19(5):1250–6.
   PubMedGoogle Scholar
• Zenker G, Költringer P. Lipoprotein (a) as a strong indicator for cerebrovascular disease. Stroke 1986;17(5):942–5.
   PubMedGoogle Scholar
• Woo J, Lau E. Hypertension, lipoprotein (a) and apolipoprotein A-1 as risk factors for stroke in the Chinese. Stroke 1991 Feb;22(2):203–8.
   PubMedGoogle Scholar
• Henry JMB, Bennet MS, Mohr JP, Stroke: pathophysiology, diagnosis and management. 2nd ed. New York, USA: Churchill Livingstone Inc.; 1992; 3–29.
   Google Scholar
• Cobbaert C, Arentsen JC, Mulder P, Significance of various parameters derived from biological variability of lipoprotein(a), homocysteine, cysteine, and total antioxidant status. Clin Chem 1997 Oct;43(10):1958–64.
   PubMed Web of Science ®Google Scholar
• Banks JL, Marotta CA. Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis. Stroke 2007 Mar;38(3): 1091–6.
   PubMed Web of Science ®Google Scholar
• Adams HP, Bendixen BH, Kapelle LJ, Classification of subtype of acute ischemic stroke. Stroke 1993 Jan;24(1):35–41.
   PubMed Web of Science ®Google Scholar
• Demirkiran MK. Homosistein ve serebral vasküler hastalıklar. Kocatepe Tıp Dergisi 2003;1:8–13.
   Google Scholar
• Howard VJ, Sides EG, Newman GC, Changes in plasma homocysteine in the acute phase after stroke. Stroke 2002 Feb;33(2):473–8.
   PubMedGoogle Scholar
• Velioglu SK, Boz C, Ari N, Iskemik strokta akut ve subakut donemde homosistein duzeyleri. Turk Serebrovaskuler Hastaliklar Dergisi 2003;9:1–5.
   Google Scholar
• Temel I, Ozerol E. Homosistein metabolizma bozukluklari ve vaskuler hastaliklarla iliskisi. Inonu Universitesi Tip Fakultesi Dergisi 2002;9(2):149–57.
   Google Scholar
• Refsum H, Fiskerstrand T, Guttormsen AB, Assessment of homocysteine status. J Inherit Metab Dis 1997 Jun;20(2):286–94.
   PubMedGoogle Scholar
• Brattsttröm L, Lindgren A, Israelsson B, Hyperhomocysteinaemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors. Eur J Clin Invest 1992 Mar;22(3):214–21.
   PubMedGoogle Scholar
• Perry IJ, Refsum H, Morris RW, Prospective study of serum total homocysteine concentration and risk of stroke in middle-ages British men. Lancet 1995 Nov 25;346(8987):1395–8.
   PubMed Web of Science ®Google Scholar
• Meiklejohn DJ, Vickers MA, Dijkhuisen R, Plasma homocysteine concentrations in the acute and convalescent periods of atherothrombotic stroke. Stroke 2001 Jan;32(1):57–62.
   PubMedGoogle Scholar
• Senarentne M P, Griffiths J, Nagendran J. Elevation of plasma homocysteine levels associated with acute myocardial infarction. Clin Invest Med 2000 Aug;23(4):220–6.
   PubMedGoogle Scholar
• Turgut C, Aluclu MF, Kale E. Serum homocysteine levels in acute cerebral infarct. Dicle Med J 2004;31:(1)36–9.
   Google Scholar
• Lindgren A, Brattström L, Norrving B, Plasma homocysteine in acute and convalescent phases after stroke. Stroke 1995 May;26(5):795–800.
   PubMedGoogle Scholar
• Alpert MA. Homocysteine, atherosclerosis and thrombosis. Southern Med J 1999;92(9):858–65.
   PubMedGoogle Scholar
• Craig WY, Ledue TB. Lipoprotein (a) and the acute phase response. Clin Chim Acta 1992;210(3):231–2.
   PubMedGoogle Scholar
• Költringer P, Jürgens GA. A dominant role of lipoprotein (a) in the investigation and evaluation of parameters indicating the development of cervical atherosclerosis. Atherosclerosis 1985 Dec;58(1–3):187–98.
   PubMedGoogle Scholar
• Jürgens G, Költringer P. Lipoprotein (a) in ischemic cerebrovascular disease: a new approach to the assessment of risk for stroke. Neurology 1987 Mar;37(3):513–5.
   PubMedGoogle Scholar
• Hachinski V, Graffagnino C, Beaudry M, Lipids and stroke paradox resolved. Arch Neurol 1996 Apr;53(4):303–8.
   PubMedGoogle Scholar
• Kuusi T, Yki-Järvinen H, Kauppinen-Mäkelin R, Effect of insulin treatment on serum lipoprotein (a) in non-insulin-dependent diabetes. Eur J Clin Invest. 1995;25(3):194–200.
   PubMedGoogle Scholar
• Longenecker JC, Klag MJ, Marcovina SM, Small apolipoprotein(a) size predicts mortality in end-stage renal disease: the CHOICE Study. Circulation 2002 Nov 26;106(22):2812–8.
   PubMedGoogle Scholar
• Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci U S A 1992 Nov 1;89(21):10193–7.
   PubMedGoogle Scholar
• Tascilar N, Ekem S, Aciman E. Hyperhomocysteinemia as an independent risk factor for cardioembolic stroke in Turkish population. Tohoku J Exp Med 2009 Aug;218(4):293–300.
   PubMed Web of Science ®Google Scholar
• van Kooten F, van Krimpen J, Dippel DW. Lipoprotein (a) in patients with acute cerebral ischemia. Stroke 1996;27(7):1231–5.
   PubMedGoogle Scholar
• Woo J, Lam CWK. Acute and long-term changes in serum lipids after acute stroke. Stroke 1990;21(10):1407–11.
   PubMedGoogle Scholar
• Kado DM, Bucur A, Selhub J, Homocysteine levels and decline in physical function: MacArthur studies of successful aging. Am J Med 2002;113(7):537–42.
   PubMed Web of Science ®Google Scholar
• Cui R, Moriyama Y, Koike KA, Serum total homocysteine concentrations and risk of mortality from stroke and coronary heart disease in Japanese: the JACC study. Atherosclerosis 2008 Jun;198(2):412–8.
   PubMed Web of Science ®Google Scholar
• Iso H, Moriyama Y, Sato S, Serum total homocysteine concentrations and risk of stroke and its subtypes in Japanese. Circulation 2004;109(22):2766–72.
   PubMed Web of Science ®Google Scholar
• Bostom AG, Rosenberg IH, Silbershatz H, Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham study. Ann Intern Med 1999;131(5):352–5.
   PubMedGoogle Scholar
• Sacco RL, Anand K, Lee HS, Homocysteine and the risk of ischemic stroke in a triethnic cohort: the Northern Manhattan study. Stroke 2004;35(10):2263–9.
   PubMedGoogle Scholar
• Mizrahi EH, Fleissig Y, Arad M, Plasma homocysteine level and functional outcome of patients with ischemic stroke. Arch Phys Med Rehabil 2005;86(1):60–3.
   PubMedGoogle Scholar